Table 2. Association of Renin-Angiotensin System (RAS) Inhibitor Therapy and Quality-of-Life Scale in Data Set Resulting From the Propensity Analysisa.
| Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)b | RAS Inhibitor Prescription (n = 2416) |
No Prescription (n = 2421) |
Between-Group Differencec | P Value |
|---|---|---|---|---|
| Median score at baseline (interquartile range) | 42.7 (26.0 to 61.5) | 43.1 (25.5 to 61.5) | ||
| Median score at 1 y (interquartile range) | 83.3 (66.2 to 94.4) | 82.3 (64.1 to 93.8) | ||
| Change in score | 33.3 (14.2 to 51.0)d | 31.3 (13.5 to 51.1)d | 2.10 (0.10 to 4.06)e | <.001f |
| Change in score >20 points, No. (%) | 1649 (68.3) | 1591 (65.7) | 2.54 (−0.11 to 5.19)g | .06 |
| Change in score between >20 and ≥60 points at 1 y, No. (%) | 1475 (61.1) | 1412 (58.3) | 2.73 (−0.04 to 5.49)g | .05 |
| Favorable outcome, No. (%)h | 1904 (78.8) | 1862 (76.9) | 1.90 (−0.44 to 4.24)g | .11 |
To reduce the effect of selection bias in the KCCQ cohort, the inverse probability weighting framework was used to increase the weight of available patients who were most like those with missing follow-up data. This process involved constructing a multivariable logistic regression model to determine the probability of having missing KCCQ follow-up data. In addition to treatment group, the model included the same variables listed in eAppendix 2 in the Supplement.
A patient-reported, disease-specific health status instrument (range, 0-100); a higher score indicates less symptom burden and better quality of life. A change in score of 5 points corresponds to small clinical improvements; 10 points, moderate; and 20 points, large.
Expressed as percentages unless otherwise indicated.
Expressed as a median (interquartile range). Formula: (score with RAS inhibitor therapy at 1 year minus score at baseline) minus (score with no prescription at 1 year minus score at baseline).
Expressed as difference in improvement (95% CI). Formula: (RAS inhibitor therapy group) minus (no prescription group).
An analysis of covariance was performed. Change in KCCQ-OS from baseline adjusted for RAS inhibitor therapy in the presence of baseline KCCQ-OS.
Expressed as a risk difference (95% CI). Formula: (RAS inhibitor therapy group) minus (no prescription group).
Defined as survival with a reasonable quality of life (KCCQ-OS score ≥60) without any meaningful worsening (decrease of ≥10 points in the KCCQ-OS score from baseline to 1 year).